Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He is currently finishing up a Master’s degree in communications at Georgetown University.

Latest Posts

FDA: Vaccines a Critical Tool in Protecting and Promoting Public Health

FDA115x76

Yesterday, Dr. Karen Midthun of the FDA wrote about the important role of vaccines in promoting public health: Vaccines are a critical tool in protecting and promoting the public health in the U.S. and around the world. The risks from childhood diseases like measles, mumps and polio have been greatly reduced, or in the case of polio, eliminated in the U.S. Vaccines are one of the great public health success stories of the 20th century. Dr. Midlun Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The Economist – Biotechnology: Fever Rising

The-Economist-115x76

After speaking with several attendees and speakers at last week’s BIO CEO & Investor Conference, the Economist featured an article this week about the strong performance of biotech equities recently: AS INVESTORS and executives crammed into a New York ballroom for a conference held this week by the Biotechnology Industry Organisation, the mood was jittery. The previous week eight biotech firms had launched initial public offerings in America, together raising more than $500m. In a discussion Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , ,

Business Roundtable: The Reimbursement Landscape under ACA

Capture

As the Affordable Care Act is implemented, reimbursement for life-saving and life-enhancing drugs is one of the most pressing issues facing healthcare stakeholders and decision makers, including patients, payers, providers, and innovative drug developers. BIO hosted a business roundtable discussion on this timely topic yesterday at our 16th Annual BIO CEO & Investor Conference. Moderated by Real Endpoint’s Roger Longman, panelists represented a variety of perspectives: Peter Bach, MD, MAPP, Attending Physician, Memorial Sloan-Kettering Cancer Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Sanofi’s Chris Viehbacher: Trust, Respect Key in Pharma-Biotech Partnerships

33713_Viehbacher_100x100 copy

How can large pharmaceutical and small biotech companies form mutually beneficial partnerships that harness the strengths of each side in order to bring new therapies to patients? Sanofi CEO and Genzyme Chairman Chris Viehbacher shared his thoughts on that question and several other topics, including the growing importance of emerging markets, at a Fireside Chat at the 16th Annual BIO CEO & Investor Conference on Monday. He reflected that as the leader of a big pharma Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Responds to GPhA Citizen Petition on Biosimilars Naming

FDA115x76

Last September, the Generic Pharmaceutical Association (GPhA) filed a Citizen Petition with the FDA, requesting the FDA to “implement its INN naming policy equally to all biologics” and to require “all biologics approved under the Section 351(k) pathway…share the same INN [International Nonproprietary Name] as the RPP [reference protein product]” (the GPhA Petition). Today, BIO submitted our response. Contrary to the GPhA Petition, BIO believes that the legal, regulatory, and scientific principles related to biologics and biosimilarity Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,